Refine by
Hiv 1 Articles & Analysis
11 news found
Frontier Biotechnologies announced that the Azerbaijan Republic Ministry of Health approved Aikening® (Albuvirtide), the first long-acting intravenous infusion for the treatment of HIV-1 infection in adults. Aikening® is a new fusion inhibitor given once weekly, used in combination dual therapy to treat people living with HIV who have ...
Continued the recruitment for two Phase 2 clinical trials of BIT225 for treatment of HIV-1 infection at sites in Australia and Thailand. Continued the design, synthesis and testing of new compounds under its HIV-1 program, with the aim of identifying a next generation lead anti-HIV-1 drug. ...
It is world’s 1st long-acting HIV-1 fusion inhibitor (once-a-week injection). China NMPA approved its marketing authorization in 2018. It’s indicated for treatment-experienced HIV-1 patients who still have viral replication, combining with any ARVs. ...
The TALENT study (TALENT) findings, which were presented at the 11th International AIDS Society (IAS) Conference on HIV Science, showed that a two-drug regimen was as effective and safe as multi-drug therapies TALENT is the world's first phase III clinical trial of the new long-acting HIV-1 fusion inhibitor, Aikening® (generic name: ...
• The study of Tnp Tn5 is important because of its similarity to HIV-1 and other retroviral diseases. • By studying Tn5, more about other transposases and their activities can also be discovered. ...
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering GPCR-targeted therapeutics, today announced the results of their Phase 1 study of OB-002H which is an investigational candidate microbicide for HIV prevention. ...
Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific MAS Omni Infectious Disease quality control sets for monitoring serological assays for analytes such as HIV 1&2, Hepatitis B & C virus, Syphilis and HTLV I/II. Serology testing for infectious diseases continues to be on the rise and ...
As scientists scramble to learn more about the SARS-CoV-2 coronavirus, two recent studies of the virus’ genome reached controversial conclusions: namely, that snakes are intermediate hosts of the new virus, and that a key coronavirus protein shares “uncanny similarities” with an HIV-1 protein. Now, a study in ACS’ Journal of Proteome ...
Investigators discuss in "a(1)Proteinase Inhibitor Regulates CD4 Lymphocyte Levels and Is Rate Limiting in HIV-1 Disease" new findings in HIV/AIDS. ...
Abbott and the Clinton Health Access Initiative (CHAI) have joined forces to provide HIV testing to infants in all countries working in partnership with the CHAI. A key focus of this cooperation will be sub-Saharan Africa, which the World Health Organization estimates to account for 90 percent of global HIV infections in children. Under terms of the agreement, ...
According to recent research from New York, HLE "interacts with HIV-1 glycoprotein (gp)41, suggesting a nonenzymatic receptor function for HLE in the context of HIV-1." "HLE is found localized to the cell surface, but not granules in HIV permissive clones, and to granules, but not the cell surface of ...